logo
Sign up Today and Receive Breaking News, Views, Rumors, Alerts, and Information on Micro Cap Stocks.
Name: Email:
Get our FREE Newsletter!
top
tl top tl
left
Home
left
tl top tl
left
Market News
left
tl top tl
left
Companies
left
tl top tl
left
Daily Reports
left
tl top tl
left
Options Chat Rooms
left
     
 
GRP
 
 
IE
 
bmm
 
penny
 
st
 
td
 
pinksheets
 
 
 
 
TopStories
trans
 
(COMTEX) B: BioElectronics Corp. (Pink Sheets: BIEL) News Alert ( M2 )
Tuesday 17th of November 2009

 Las Vegas NV, Nov 17, 2009 (M2 PRESSWIRE via COMTEX) -- BioElectronics Corp. (Pink Sheets: BIEL). Monday's Headline: BioElectronics Technology More Effective Than Extra Strength Tylenol(R) in Reducing Muscle Soreness in Clinical Study

BioElectronics Corp. (Pink Sheets: BIEL) on Monday after the closing bell announced that its disposable drug-free anti-inflammatory devices proved to be significantly more effective than acetaminophen in a clinical study of Delayed Onset Muscle Soreness (DOMS). According to the company's press release the study included more than 100 healthy male and female college athletes and trainers which were given a vigorous resistance exercise regimen to induce DOMS.

The study tested the effectiveness of ActiPatch Therapy versus acetaminophen in reducing the pain of Delayed Onset Muscle Soreness, a condition associated with increased physical exertion. Participants were divided randomly into three groups; a group that used ActiPatch for two days, a control group that received no treatment, and a third group that was to be treated with acetaminophen.

Sheena Kong, M.D. the principal investigator commented, "The study was conclusive showing that the ActiPatch treated volunteers had significantly less pain than those in either the acetaminophen or control groups. Also of note was the fact that some of the participants assigned to the acetaminophen group were eliminated from the results because they expressed reservations about consuming the drug." For more information CONTACT: Media/IR Joe Noel (925) 922-2560

Sector: Biomedical

Industry: Biotech

Get ahead of the market with www.PreMarketData.com ALERTS for FREE!

Sign up for our FREE newsletter at www.premarketdata.com

Join us on twitter at www.twitter.com/premarketdata

If it's stock market news, GET it at www.PreMarketData.com

Get valuable exposure for your company through www.PreMarketData.com by contacting us at: Contact: info@PreMarketData.com

Join PreMarketData.com's large community of Wall St. professionals to receive news, views and alerts. It's always free to our subscribers at www.PreMarketData.com

About - PreMarketData.com is a premier information destination for breaking News, Profiles, and Alerts on Micro, Small, Mid, and Large Cap Stocks. PreMarketData.com publishes pre-market, early and mid-session reports including Op-Ed and informational pieces globally and on its web site. Join other Wall Street professionals and subscribe to our FREE newsletter giving you a head start on what's hot in the market.

Disclaimer

PreMarketData.com is a wholly owned subsidiary of Investors Direct Inc. The material contained in this is release is intended to be strictly informational. This article may contain forward looking statements. The accuracy and completeness of the information supplied is not warranted and is derived from a variety of sources and third parties which may or may not be reliable. Investors Direct Inc. and PreMarketData.com disclaim any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may also contain technical inaccuracies or typographical errors. This material is being provided for informational purposes only. PreMarketData.com is NOT a registered investment advisor or a broker dealer. This information neither is, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by Investors Direct Inc., or PreMarketData.com. PreMarketData.com does not offer or provide any investment advice or opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make. Such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs. PreMarketData.com or its officers and directors may hold positions in the companies mentioned in this report. PreMarketData.com may also receive compensation from companies mentioned in this report so please read our compensation disclosure which can be found at www.PreMarketData.com. At this time PreMarketData.com has not been compensated by any of the companies mentioned in this report. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and PreMarketData.com undertakes no obligation to update such statements.

At the time of this report PreMarketData.com holds no position in BIEL.

Always do your own due diligence. Visit our web site, www.PreMarketData.com for further risks and disclosures.

CONTACT:

PreMarketData.com e-mail: info@premarketdata.com Tel: +1 702 544 2396 ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com. (C)1994-2009 M2 COMMUNICATIONS *** end of story ***

 
back
 
 
ftg trans ftg
lg
Contact Us  |  Terms of Use  |  Privacy Policy  |  Disclaimer  |  Compensation Disclosure
lg
lg rg
blg trans brg